Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure

Inclusion Criteria: * Age 40 to 79 * Patients with ischemic heart failure： * LVEF less than or equal to 45% measured by echocardiography in modified Simpson method * History of prior myocardial infarction with or without percutaneous coronary intervention (PCI) or/and coronary artery bypass grafting (CABG); * Coronary angiography (CAG) or coronary CTA shows more than or equal to 50% stenosis in at least one of the main coronary arteries with or without revascularization, of which the researcher thinks that it is closely related to heart failure; * With or without dyspnea, fatigue and fluid retention (edema) etc. * History of heart failure or present with heart failure symptoms for at least 3 months; * New York Heart Association (NYHA) Class II to IV; * Submitted informed consent Exclusion Criteria: * Acute heart failure or acute exacerbation of chronic heart failure * Those who have one of the following diseases: * Acute coronary syndrome within 30 days * Revascularization therapy within 6 months * Uncontrolled hypertension with systolic pressure more than or equal to 180mmHg and/or diastolic pressure more than or equal to 110mmHg * Second degree type 2 or worse sinoatrial/atrioventricular block without implantation of pacemaker or uncontrolled malignant cardiac arrhythmia * Dilated cardiomyopathy * Hypertrophic obstructive cardiomyopathy * Myocarditis * Pulmonary artery embolism * Severe valvular heart disease * Pulmonary heart disease * Stroke within 6 months * Cardiac resynchronization therapy * Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days * Severe endocrine diseases such as hyperthyroidism, etc. * History of malignant tumor * Hemoglobin (HB )≤ 9g/dl * Alanine aminotransferase (ALT) \> 2 times the upper limit of normal * Serum creatinine \> 265 μmol/L * Mental disorder * Being pregnant, planning for pregnancy or breastfeeding * Suspicious or definite allergy to intervention drugs * Participated in other trials within 2 months * Unable to walk autonomously due to physical disabilities